341 related articles for article (PubMed ID: 34018075)
1. Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.
Shandilya A; Mehan S
Neurol Sci; 2021 Aug; 42(8):3145-3166. PubMed ID: 34018075
[TBL] [Abstract][Full Text] [Related]
2. Activation of IGF-1/GLP-1 Signalling via 4-Hydroxyisoleucine Prevents Motor Neuron Impairments in Experimental ALS-Rats Exposed to Methylmercury-Induced Neurotoxicity.
Shandilya A; Mehan S; Kumar S; Sethi P; Narula AS; Alshammari A; Alharbi M; Alasmari AF
Molecules; 2022 Jun; 27(12):. PubMed ID: 35745001
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of extracellular regulated kinase (ERK)-1/2 signaling pathway in the prevention of ALS: Target inhibitors and influences on neurological dysfunctions.
Sahu R; Upadhayay S; Mehan S
Eur J Cell Biol; 2021; 100(7-8):151179. PubMed ID: 34560374
[TBL] [Abstract][Full Text] [Related]
4. Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions.
Bhalla S; Mehan S; Khan A; Rehman MU
Neurosci Biobehav Rev; 2022 Nov; 142():104896. PubMed ID: 36191807
[TBL] [Abstract][Full Text] [Related]
5. Understanding Abnormal c-JNK/p38MAPK Signaling Overactivation Involved in the Progression of Multiple Sclerosis: Possible Therapeutic Targets and Impact on Neurodegenerative Diseases.
Singh A; Upadhayay S; Mehan S
Neurotox Res; 2021 Oct; 39(5):1630-1650. PubMed ID: 34432262
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor signaling system and ALS neurotrophic factor treatment strategies.
Festoff BW; Yang SX; Vaught J; Bryan C; Ma JY
J Neurol Sci; 1995 May; 129 Suppl():114-21. PubMed ID: 7595601
[TBL] [Abstract][Full Text] [Related]
7. Understanding Abnormal c-JNK/p38MAPK Signaling in Amyotrophic Lateral Sclerosis: Potential Drug Targets and Influences on Neurological Disorders.
Yadav RK; Minz E; Mehan S
CNS Neurol Disord Drug Targets; 2021; 20(5):417-429. PubMed ID: 33557726
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.
Sakowski SA; Schuyler AD; Feldman EL
Amyotroph Lateral Scler; 2009 Apr; 10(2):63-73. PubMed ID: 18608100
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor system in amyotrophic lateral sclerosis.
Wilczak N; Keyser J
Endocr Dev; 2005; 9():160-169. PubMed ID: 15879696
[TBL] [Abstract][Full Text] [Related]
10. Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage.
Siddiqui EM; Mehan S; Bhalla S; Shandilya A
Curr Res Neurobiol; 2022; 3():100055. PubMed ID: 36685765
[TBL] [Abstract][Full Text] [Related]
11. Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: targets for disease modification?
Bassil F; Fernagut PO; Bezard E; Meissner WG
Prog Neurobiol; 2014 Jul; 118():1-18. PubMed ID: 24582776
[TBL] [Abstract][Full Text] [Related]
12. The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features.
Pellecchia MT; Pivonello R; Monsurrò MR; Trojsi F; Longo K; Piccirillo G; Pivonello C; Rocco M; Di Somma C; Colao A; Tedeschi G; Barone P
Eur J Neurol; 2010 May; 17(5):666-71. PubMed ID: 20002733
[TBL] [Abstract][Full Text] [Related]
13. The role of insulin-like growth factor 1 in ALS cell and mouse models: A mitochondrial protector.
Wen D; Cui C; Duan W; Wang W; Wang Y; Liu Y; Li Z; Li C
Brain Res Bull; 2019 Jan; 144():1-13. PubMed ID: 30414993
[TBL] [Abstract][Full Text] [Related]
14. Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients.
Doré S; Krieger C; Kar S; Quirion R
Brain Res Mol Brain Res; 1996 Sep; 41(1-2):128-33. PubMed ID: 8883943
[TBL] [Abstract][Full Text] [Related]
15. Sporadic amyotrophic lateral sclerosis (SALS) - skeletal muscle response to cerebrospinal fluid from SALS patients in a rat model.
Shanmukha S; Narayanappa G; Nalini A; Alladi PA; Raju TR
Dis Model Mech; 2018 Apr; 11(4):. PubMed ID: 29666144
[TBL] [Abstract][Full Text] [Related]
16. Autocrine production of IGF-I increases stem cell-mediated neuroprotection.
Lunn JS; Sakowski SA; McGinley LM; Pacut C; Hazel TG; Johe K; Feldman EL
Stem Cells; 2015 May; 33(5):1480-9. PubMed ID: 25532472
[TBL] [Abstract][Full Text] [Related]
17. Impairments to the GH-IGF-I axis in hSOD1G93A mice give insight into possible mechanisms of GH dysregulation in patients with amyotrophic lateral sclerosis.
Steyn FJ; Ngo ST; Lee JD; Leong JW; Buckley AJ; Veldhuis JD; McCombe PA; Chen C; Bellingham MC
Endocrinology; 2012 Aug; 153(8):3735-46. PubMed ID: 22621959
[TBL] [Abstract][Full Text] [Related]
18. The multifaceted role of the CXC chemokines and receptors signaling axes in ALS pathophysiology.
La Cognata V; Morello G; Guarnaccia M; Cavallaro S
Prog Neurobiol; 2024 Apr; 235():102587. PubMed ID: 38367748
[TBL] [Abstract][Full Text] [Related]
19. Brain GLP-1/IGF-1 Signaling and Autophagy Mediate Exendin-4 Protection Against Apoptosis in Type 2 Diabetic Rats.
Candeias E; Sebastião I; Cardoso S; Carvalho C; Santos MS; Oliveira CR; Moreira PI; Duarte AI
Mol Neurobiol; 2018 May; 55(5):4030-4050. PubMed ID: 28573460
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide-1 cleavage product GLP-1(9-36) reduces neuroinflammation from stroke via the activation of insulin-like growth factor 1 receptor in astrocytes.
Huang J; Liu Y; Cheng L; Li J; Zhang T; Zhao G; Zhang H
Eur J Pharmacol; 2020 Nov; 887():173581. PubMed ID: 32949596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
